ICU Medical Inc. is a leading medical device company that specializes in the development and manufacturing of innovative products for intravenous therapy, infusion systems, and related applications
The company focuses on enhancing patient safety and improving clinical outcomes through its advanced technologies, including smart infusion systems and closed-loop medication delivery solutions. With a commitment to quality and reliability, ICU Medical serves a wide range of healthcare settings, helping to streamline hospital operations and enhance the overall patient experience. Their extensive portfolio also encompasses vital components used in various healthcare environments, underscoring their role as a crucial player in the medical technology sector.
Medical device company ICU Medical (NASDAQICUI) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 7.1% year on year to $629.8 million. Its non-GAAP profit of $2.11 per share was 42.4% above analysts’ consensus estimates.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSEAORT) and its peers.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including ICU Medical (NASDAQICUI) and its peers.
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSEPEN) and its peers.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems (NASDAQMMSI) and its peers.
Smiths Medical, a subsidiary of ICU Medical, recalls Bivona neonatal, pediatric, and adult tracheostomy tubes due to a defect that may lead to serious injury or death following the FDA's classification of the issue as a serious health risk.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Gainers PaxMedica, Inc. (NASDAQPXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
